Teleflex Incorporated (NYSE:TFX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Teleflex Incorporated (NYSE:TFX) has been given an average rating of “Moderate Buy” by the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $267.50.

A number of research analysts have issued reports on the company. Royal Bank of Canada cut their price objective on Teleflex from $272.00 to $265.00 and set an “outperform” rating for the company in a report on Friday, February 23rd. StockNews.com cut Teleflex from a “buy” rating to a “hold” rating in a report on Friday, February 23rd. Truist Financial cut their price objective on Teleflex from $270.00 to $265.00 and set a “hold” rating for the company in a report on Friday, February 23rd. Finally, JMP Securities reissued a “market outperform” rating and set a $285.00 price objective on shares of Teleflex in a report on Friday, February 23rd.

Teleflex Stock Down 0.4 %

TFX opened at $207.38 on Friday. Teleflex has a fifty-two week low of $177.63 and a fifty-two week high of $276.43. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.32 and a quick ratio of 1.29. The firm’s fifty day moving average price is $226.40 and its two-hundred day moving average price is $225.08. The company has a market capitalization of $9.77 billion, a P/E ratio of 27.54, a P/E/G ratio of 2.01 and a beta of 1.11.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, February 22nd. The medical technology company reported $3.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.26 by $0.12. Teleflex had a net margin of 11.98% and a return on equity of 14.98%. The firm had revenue of $773.90 million for the quarter, compared to the consensus estimate of $769.01 million. During the same quarter in the previous year, the company earned $3.52 earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. On average, analysts anticipate that Teleflex will post 13.73 EPS for the current year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 15th. Investors of record on Friday, March 1st were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $1.36 annualized dividend and a yield of 0.66%. Teleflex’s dividend payout ratio (DPR) is 18.06%.

Insider Buying and Selling

In other Teleflex news, VP Cameron P. Hicks sold 7,401 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the completion of the sale, the vice president now directly owns 10,050 shares of the company’s stock, valued at approximately $2,261,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.43% of the stock is owned by corporate insiders.

Institutional Trading of Teleflex

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Michigan Retirement System increased its stake in shares of Teleflex by 0.8% in the 1st quarter. State of Michigan Retirement System now owns 12,917 shares of the medical technology company’s stock valued at $2,921,000 after acquiring an additional 100 shares during the last quarter. Buffington Mohr McNeal increased its stake in shares of Teleflex by 4.7% in the 1st quarter. Buffington Mohr McNeal now owns 4,480 shares of the medical technology company’s stock valued at $1,013,000 after acquiring an additional 200 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Teleflex by 15.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 26,319 shares of the medical technology company’s stock valued at $5,953,000 after acquiring an additional 3,597 shares during the last quarter. Thompson Investment Management Inc. increased its stake in shares of Teleflex by 8.5% in the 1st quarter. Thompson Investment Management Inc. now owns 2,540 shares of the medical technology company’s stock valued at $574,000 after acquiring an additional 200 shares during the last quarter. Finally, Riverview Trust Co bought a new stake in shares of Teleflex in the 1st quarter valued at about $31,000. 95.62% of the stock is owned by institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.